HC Wainwright & Co. Reiterates Buy on ADMA Biologics, Maintains $4.5 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ADMA Biologics (NASDAQ:ADMA) with a Buy and maintains $4.5 price target.

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ADMA Biologics (NASDAQ:ADMA) with a Buy and maintains $4.5 price target.

Total
0
Shares
Related Posts